SAB Biotherapeutics, Inc. (SABS) Institutional Ownership

Ownership Summary

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has 48 institutional investors with active 13F positions as of December 2025.

• Their combined ownership stood at 46.7% of outstanding shares in December 2025, up from 36.0% in September 2025.
• Their total shares held in SABS increased 37.82% from the prior quarter, while the number of investors in SAB Biotherapeutics increased 84.62% year over year.
• Of these 48 holders, 32 added to their stakes in SAB Biotherapeutics, 4 trimmed positions, and 12 made no changes.
• Institutional investors collectively held 36.37Mn shares in SAB Biotherapeutics as of December 2025, up by 9.98Mn shares quarter on quarter, and up 33.7Mn shares year over year.
• Vivo Capital, LLC is the top holder of SAB Biotherapeutics as of December 31, 2025, with 11.42Mn shares representing 14.67% of outstanding stock.
• Leading buyers of SAB Biotherapeutics shares for the quarter ending December 2025 were Caligan Partners LP (7.97Mn), PERCEPTIVE ADVISORS LLC (5.63Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.41Mn), BALYASNY ASSET MANAGEMENT L.P. (3.28Mn), MILLENNIUM MANAGEMENT LLC (2.71Mn).
• The largest sales of SABS for the quarter ending December 2025 came from Blackstone Inc. (1.28Mn), Simplify Asset Management Inc. (21.0K), OMERS ADMINISTRATION Corp (12.3K), Qube Research & Technologies Ltd (7.05K), Focus Partners Wealth (5.16K).
• Per Business Quant data, the top 10 holders of SAB Biotherapeutics for the quarter ending December 2025 are Vivo Capital, LLC (11.42Mn), Caligan Partners LP (7.97Mn), PERCEPTIVE ADVISORS LLC (6.43Mn), Commodore Capital LP (4.4Mn), RA CAPITAL MANAGEMENT, L.P. (4.4Mn), BALYASNY ASSET MANAGEMENT L.P. (3.76Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.41Mn), MILLENNIUM MANAGEMENT LLC (3.03Mn), Woodline Partners LP (2.85Mn), VANGUARD CAPITAL MANAGEMENT LLC (2.49Mn).